{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T22:36:45Z","timestamp":1772577405735,"version":"3.50.1"},"reference-count":35,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,11,19]],"date-time":"2020-11-19T00:00:00Z","timestamp":1605744000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.vaccine.2020.11.018","type":"journal-article","created":{"date-parts":[[2020,11,23]],"date-time":"2020-11-23T21:02:25Z","timestamp":1606165345000},"page":"431-437","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["Impact and effectiveness of the 10-valent pneumococcal conjugate vaccine on invasive pneumococcal disease among children under 5\u00a0years of age in the Netherlands"],"prefix":"10.1016","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1774-0975","authenticated-orcid":false,"given":"L.","family":"Peckeu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"van der Ende","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.E.","family":"de Melker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.A.M.","family":"Sanders","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.J.","family":"Knol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2020.11.018_b0005","unstructured":"World Health Organization. Pneumococcal conjugate vaccine for childhood immunization\u2014WHO position paper. 2007;82:93\u2013104."},{"issue":"16","key":"10.1016\/j.vaccine.2020.11.018_b0010","first-page":"877","article-title":"Global, regional, and national burden of neurological disorders during 1990\u20132015: a systematic analysis for the Global Burden of Disease Study","volume":"2017","author":"Feigin","year":"2015","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.vaccine.2020.11.018_b0015","doi-asserted-by":"crossref","first-page":"e31","DOI":"10.1371\/journal.pgen.0020031","article-title":"Genetic analysis of the capsular biosynthetic locus from all 90 pneumococcal serotypes","volume":"2","author":"Bentley","year":"2006","journal-title":"PLoS Genet"},{"key":"10.1016\/j.vaccine.2020.11.018_b0020","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1128\/CMR.00024-15","article-title":"Pneumococcal capsules and their types: past, present, and future","volume":"28","author":"Geno","year":"2015","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.vaccine.2020.11.018_b0025","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1086\/648593","article-title":"Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine","volume":"201","author":"Pilishvili","year":"2010","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2020.11.018_b0030","unstructured":"VIEW-hub[Internet]. PCV: Current vaccine intro status."},{"key":"10.1016\/j.vaccine.2020.11.018_b0035","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1016\/j.vaccine.2015.04.005","article-title":"Effectiveness of three pneumococcal conjugate vaccines to prevent invasive pneumococcal disease in Quebec, Canada","volume":"33","author":"Deceuninck","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.11.018_b0040","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/S2213-2600(14)70060-8","article-title":"Effectiveness of ten-valent pneumococcal conjugate vaccine against invasive pneumococcal disease in Brazil: a matched case-control study","volume":"2","author":"Domingues","year":"2014","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.vaccine.2020.11.018_b0045","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1016\/j.vaccine.2018.03.001","article-title":"Long-term impact of 10-valent pneumococcal conjugate vaccination on invasive pneumococcal disease among children in Finland","volume":"36","author":"Rinta-Kokko","year":"2018","journal-title":"Vaccine"},{"issue":"1780\u201390","key":"10.1016\/j.vaccine.2020.11.018_b0050","article-title":"Comparison of the impact of pneumococcal conjugate vaccine 10 or pneumococcal conjugate vaccine 13 on invasive pneumococcal disease in equivalent populations","volume":"65","author":"Naucler","year":"2017","journal-title":"Clin Infect Dis"},{"issue":"196","key":"10.1016\/j.vaccine.2020.11.018_b0055","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1086\/521626","article-title":"Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination","volume":"1998\u20132004","author":"Hicks","year":"2007","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2020.11.018_b0060","doi-asserted-by":"crossref","first-page":"2956","DOI":"10.1128\/IAI.71.5.2956-2959.2003","article-title":"Pneumococcal serotype 19F conjugate vaccine induces cross-protective immunity to serotype 19A in a murine pneumococcal pneumonia model","volume":"71","author":"Jakobsen","year":"2003","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2020.11.018_b0065","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1093\/infdis\/148.6.1136","article-title":"Considerations for formulating the second-generation pneumococcal capsular polysaccharide vaccine with emphasis on the cross-reactive types within groups","volume":"148","author":"Robbins","year":"1983","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2020.11.018_b0070","unstructured":"National Institute for Public Health and the Environment (RIVM). The National Immunisation Programme in the Netherlands: Surveillance and developments in 2017\u20132018. Het Rijksvaccinatieprogramma in Nederland: Surveillance en ontwikkelingen in 2017\u20132018: Rijksinstituut voor Volksgezondheid en Milieu RIVM."},{"issue":"2040","key":"10.1016\/j.vaccine.2020.11.018_b0075","article-title":"Invasive pneumococcal disease 3 years after introduction of 10-valent pneumococcal conjugate vaccine, the Netherlands","volume":"21","author":"Knol","year":"2015","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2020.11.018_b0080","doi-asserted-by":"crossref","first-page":"6558","DOI":"10.1016\/j.vaccine.2019.08.025","article-title":"Twelve years of pneumococcal conjugate vaccination in the Netherlands: impact on incidence and clinical outcomes of invasive pneumococcal disease","volume":"37","author":"Vestjens","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.11.018_b0085","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0028435","article-title":"Using the indirect cohort design to estimate the effectiveness of the seven valent pneumococcal conjugate vaccine in England and Wales","volume":"6","author":"Andrews","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2020.11.018_b0090","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/S1473-3099(18)30166-X","article-title":"Effectiveness of the DTPa-HBV-IPV\/Hib vaccine against invasive Haemophilus influenzae type b disease in the Netherlands (2003\u201316): a case-control study","volume":"18","author":"Monge","year":"2018","journal-title":"Lancet Infect Dis"},{"issue":"e0120290","key":"10.1016\/j.vaccine.2020.11.018_b0095","article-title":"Impact of ten-valent pneumococcal conjugate vaccination on invasive pneumococcal disease in Finnish children\u2013a population-based study","volume":"10","author":"Jokinen","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2020.11.018_b0100","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.3201\/eid1811.120329","article-title":"Invasive pneumococcal disease and 7-valent pneumococcal conjugate vaccine, the Netherlands","volume":"18","author":"van Deursen","year":"2012","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2020.11.018_b0105","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001517","article-title":"Serotype-specific changes in invasive pneumococcal disease after pneumococcal conjugate vaccine introduction: a pooled analysis of multiple surveillance sites","volume":"10","author":"Feikin","year":"2013","journal-title":"PLoS Med"},{"key":"10.1016\/j.vaccine.2020.11.018_b0110","doi-asserted-by":"crossref","DOI":"10.1016\/S1473-3099(18)30346-3","article-title":"Switch in a childhood pneumococcal vaccination program from PCV13 to PCV10: a defendable approach?","author":"Desmet","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2020.11.018_b0115","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/S1473-3099(18)30410-9","article-title":"Interpretation of the switch in a childhood pneumococcal vaccination programme from PCV13 to PCV10 in Belgium","volume":"18","author":"Izurieta","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2020.11.018_b0120","article-title":"Dynamic changes in paediatric invasive pneumococcal disease after sequential switches of conjugate vaccine in Belgium: a national retrospective observational study","author":"Desmet","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2020.11.018_b0125","unstructured":"Deceuninck G, Lefebvre B, De Serres G, et al. Effectiveness of pneumococcal conjugate vaccines (PCVs) to prevent Serotype 19A invasive pneumococcal disease (IPD) in children. ISPPD 2020 Digital Library, Abstract 835. Available at: https:\/\/isppd.kenes.com\/digital-library\/."},{"key":"10.1016\/j.vaccine.2020.11.018_b0130","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1016\/j.vaccine.2019.11.049","article-title":"Effectiveness of 10-valent pneumococcal conjugate vaccine estimated with three parallel study designs among vaccine-eligible children in Finland","volume":"38","author":"Rinta-Kokko","year":"2020","journal-title":"Vaccine"},{"issue":"37","key":"10.1016\/j.vaccine.2020.11.018_b0135","doi-asserted-by":"crossref","first-page":"4491","DOI":"10.1016\/j.vaccine.2019.06.071","article-title":"Effectiveness of the seven-valent and thirteen-valent pneumococcal conjugate vaccines in England: The indirect cohort design","volume":"2006\u20132018","author":"Andrews","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.11.018_b0140","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S1473-3099(18)30052-5","article-title":"Rapid increase in non-vaccine serotypes causing invasive pneumococcal disease in England and Wales, 2000\u201317: a prospective national observational cohort study","volume":"18","author":"Ladhani","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2020.11.018_b0145","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1093\/cid\/cit428","article-title":"Comparative immunogenicity and efficacy of 13-valent and 7-valent pneumococcal conjugate vaccines in reducing nasopharyngeal colonization: a randomized double-blind trial","volume":"57","author":"Dagan","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2020.11.018_b0150","first-page":"301","article-title":"Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance","volume":"15","author":"Moore","year":"2015","journal-title":"Infact Dis"},{"key":"10.1016\/j.vaccine.2020.11.018_b0155","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S1473-3099(14)70822-9","article-title":"Serotype-specific effectiveness and correlates of protection for the 13-valent pneumococcal conjugate vaccine: a postlicensure indirect cohort study","volume":"14","author":"Andrews","year":"2014","journal-title":"Lancet Infect Dis"},{"issue":"12","key":"10.1016\/j.vaccine.2020.11.018_b0160","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1093\/cid\/ciy920","article-title":"Effectiveness of 13-valent pneumococcal conjugate vaccine against invasive disease caused by serotype 3 in children: a systematic review and meta-analysis of observational studies","volume":"68","author":"Sings","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2020.11.018_b0165","unstructured":"World Health Organization. WHO position paper 2019;94:85\u2013104."},{"key":"10.1016\/j.vaccine.2020.11.018_b0170","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1001\/jama.2010.1290","article-title":"Pneumococcal conjugate vaccination and nasopharyngeal acquisition of pneumococcal serotype 19A strains","volume":"304","author":"van Gils","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2020.11.018_b0175","unstructured":"European Centre for Disease Prevention and Control (ECDC). Antimicrobial resistance surveillance in Europe 2018: ECDC Stockholm; 2018."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20314560?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20314560?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:51:49Z","timestamp":1759402309000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X20314560"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["S0264410X20314560"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.11.018","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact and effectiveness of the 10-valent pneumococcal conjugate vaccine on invasive pneumococcal disease among children under 5\u00a0years of age in the Netherlands","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.11.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}